Lioudis M, Zhou X, Davenport E, Nunna S, Krasa HB, Oberdhan D, Fernandes AW. Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease: a post hoc pooled analysis. BMC Neurol. 2023 Jun 22;24:182. doi: 10.1186/s12882-023-03247-6
Giner-Soriano M, Marsal JR, Gomez-Lumbreras A, Morros R. Risk of ischaemic stroke associated with antiepileptic drugs: a population-based case-control study in Catalonia. BMC Neurol. 2021 May 24;21(1):208. doi: 10.1186/s12883-021-02237-1
Giner-Soriano M, Marsal JR, Gomez-Lumbreras A, Morros R. Risk of ischaemic stroke associated with antiepileptic drugs: a population-based case-control study in Catalonia. BMC Neurol. 2021 May 24;21(1):208. doi: 10.1186/s12883-021-02237-1
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Granero R, Fernandez-Aranda F, Aymami N, Gomez-Pena M, Fagundo AB, Sauchelli S, Del Pino-Gutierrez A, Moragas L, Savvidou LG, Islam MA, Tarrega S, Menchon JM, Jimenez-Murcia S. Subtypes of pathological gambling with concurrent illegal behaviors. J Gambl Stud. 2015 Dec;31(4):1161-78. doi: 10.1007/s10899-014-9499-5.
Matlis S, Boric K, Chu CJ, Kramer MA. Robust disruptions in electroencephalogram cortical oscillations and large-scale functional networks in autism. BMC Neurol. 2015 Jun 27;15:97. doi: 10.1186/s12883-015-0355-8.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Saigi N, Espelt A, Folch C, Sarasa-Renedo A, Castellano Y, Majo X, Merono M, Brugal MT, Casabona J, REDAN Group. Differences in illegal drug consumption between native and immigrants in a large sample of injected drug users in Catalonia (Spain). Adicciones. 2014;26(1):69-76. doi: 10.20882/adicciones.136
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.